5-Aza-2/'-deoxycytidine

  • CAT Number: I002785
  • CAS Number: 2353-33-5
  • Molecular Formula: C₈H₁₂N₄O₄
  • Molecular Weight: 228.08
  • Purity: ≥95%
Inquiry Now

5-aza-2-deoxycytidine (Cat No.: I002785), also known as Deoxycytidine, is a DNA methyltransferase inhibitor, which integrates into DNA, causes DNA hypomethylation, and makes DNA replication stagnate in intra-S-phase. Decitabine is used to treat myelodysplastic syndrome (MDS). Decitabine induces cell cycle arrest and apoptosis in various cancer cell lines.

Catalog Number I002785
CAS Number 2353-33-5
Molecular Formula

C₈H₁₂N₄O₄

Purity 95%
Target DNA Methyltransferase
Solubility DMSO ≥43 mg/mL Water ≥9 mg/mL Ethanol ≥1.8 mg/mL
Storage -20°C
IC50 438 nM(HL-60); 4.38 nM(KG1a)
IUPAC Name 4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one
InChI InChI=1S/C8H12N4O4/c9-7-10-3-12(8(15)11-7)6-1-4(14)5(2-13)16-6/h3-6,13-14H,1-2H2,(H2,9,11,15)/t4-,5+,6+/m0/s1
InChIKey XAUDJQYHKZQPEU-KVQBGUIXSA-N
SMILES C1C(C(OC1N2C=NC(=NC2=O)N)CO)O
Reference

</br>1:Bioinformatic analysis of the effects and mechanisms of decitabine and cytarabine on acute myeloid leukemia. Zhou S, Liu P, Zhang H.Mol Med Rep. 2017 May 12. doi: 10.3892/mmr.2017.6581. [Epub ahead of print] PMID: 28498449 </br>2:Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: A systematic review and meta-analysis. He PF, Zhou JD, Yao DM, Ma JC, Wen XM, Zhang ZH, Lian XY, Xu ZJ, Qian J, Lin J.Oncotarget. 2017 Apr 19. doi: 10.18632/oncotarget.17241. [Epub ahead of print] PMID: 28489568 Free Article</br>3:Decitabine treatment of multiple extramedullary acute myeloid leukemia involvements after essential thrombocytemia transformation. Niscola P, Abruzzese E, Trawinska MM, Palombi M, Tendas A, Giovannini M, Scaramucci L, Cupelli L, Fratoni S, Noguera NI, Catalano G, de Fabritiis P.Acta Oncol. 2017 May 10:1-2. doi: 10.1080/0284186X.2017.1324215. [Epub ahead of print] No abstract available. PMID: 28488914 </br>4:[Effects of decitabine on proliferation capacity and TFPI-2 expression in leukemia K562 cells]. Wang FJ, Li JJ, Xie HT, Zeng YY, Liu J, Zhang J.Zhonghua Xue Ye Xue Za Zhi. 2017 Apr 14;38(4):340-343. doi: 10.3760/cma.j.issn.0253-2727.2017.04.016. Chinese. No abstract available. PMID: 28468099 </br>5:[A preliminary study on the outcome of lower-risk myelodysplastic syndrome by low-dose decitabine]. Ye L, Ren YL, Xie LL, Luo YW, Lin PP, Zhou XP, Ma LY, Mei C, Xu WL, Wei JY, Jiang HF, Zhang LM, Zeng H, Tong HY.Zhonghua Xue Ye Xue Za Zhi. 2017 Apr 14;38(4):307-312. doi: 10.3760/cma.j.issn.0253-2727.2017.04.009. Chinese. PMID: 28468092 </br>6:Successful Management of Decitabine prior to Full-Dose Idarubicin and Cytarabine in the Treatment of Refractory/Recurrent Acute Myeloid Leukemia. Zhao H, Xu L, Yang Y, Shao J, Chen P, Dong X, Gu L, Li D.Acta Haematol. 2017 Apr 27;137(4):195-200. doi: 10.1159/000464013. [Epub ahead of print] PMID: 28445872 </br>7:Erratum: Decitabine reverses TGF-β1-induced epithelial-mesenchymal transition in non-small-cell lung cancer by regulating miR-200/ZEB axis [Corrigendum]. [No authors listed]Drug Des Devel Ther. 2017 Apr 10;11:1161. doi: 10.2147/DDDT.S139012. eCollection 2017. PMID: 28435228 Free PMC Article</br>8:Atrial fibrillation is associated with hypermethylation in human left atrium, and treatment with decitabine reduces atrial tachyarrhythmias in spontaneously hypertensive rats. Doñate Puertas R, Meugnier E, Romestaing C, Rey C, Morel E, Lachuer J, Gadot N, Scridon A, Julien C, Tronc F, Chapuis B, Valla C, Janin A, Pirola L, Méjat A, Rome S, Chevalier P.Transl Res. 2017 Jun;184:57-67.e5. doi: 10.1016/j.trsl.2017.03.004. Epub 2017 Mar 30. PMID: 28427903 </br>9:Decitabine as salvage therapy for primary induction failure of acute myeloid leukemia. Niscola P, Neri B, Catalano G, Morino L, Giovannini M, Scaramucci L, Fratoni S, Noguera NI, Cordone I, de Fabritiis P.Acta Oncol. 2017 Feb 17:1-2. doi: 10.1080/0284186X.2017.1287947. [Epub ahead of print] No abstract available. PMID: 28406054 </br>10:Hypomethylation agent decitabine restores drug sensitivity by depressing P-glycoprotein activity through MAPK signaling pathway. Wang H, Wang X, Liao A, Liu Z.Mol Cell Biochem. 2017 Apr 12. doi: 10.1007/s11010-017-3022-0. [Epub ahead of print] PMID: 28405849

Request a Quote

Contact Us at MuseChem

We are committed to providing you with reliable, cost-effective solutions for your chemical needs, while ensuring your safety and comfort. Our team of experts is always available to answer your questions and help you navigate the complexities of the chemical industry.

Whether you're looking for a specific product or need help with a custom synthesis project, we're here to help you discover a new world of chemical possibilities. Contact us today to learn more about how we can assist you with all of your chemical needs.

Our goal is to make the process of ordering chemicals as seamless and hassle-free as possible. Let us know how we can assist you, and we'll get back to you as soon as possible. We look forward to hearing from you!